Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Visipaque 320 Generic Name & Formulations
Legal Class
Rx
General Description
Iodixanol 652mg/mL; soln for inj; contains sodium 1.11mg/mL, organically bound iodine 320mg/mL; preservative-free.
Pharmacological Class
Radiographic contrast medium.
See Also
How Supplied
Bottles (50mL, 100mL, 150mL, 200mL)—10
Manufacturer
Generic Availability
YES
Visipaque 320 Indications
Indications
Intra-arterial: Digital subtraction angiography, angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, and cerebral arteriography. IV: CT imaging of the head and body, excretory urography, and coronary computed tomography angiography (CCTA) to assist in the diagnostic evaluation of suspected coronary artery disease.
Visipaque 320 Dosage and Administration
Adult
≥12yrs: Usual single doses: Intra-arterial (digital subtraction angiography): Carotid or vertebral arteries: 5–8mL (max 175mL); Aortography: 10–50mL; Major branches of aorta: 2–10mL; Aortofemoral runoffs: 6–15mL; Peripheral arteries: 3–15mL (max 250mL). Intra-arterial (arteriography): Carotid arteries: 10–14mL; Vertebral arteries: 10–12mL (max 175mL); Right coronary artery: 3–8mL; Left coronary artery: 3–10mL; Left ventricle: 20–45mL (max 200mL); Renal arteries: 8–18mL; Aortography: 30–70mL; Major branches of aorta: 10–70mL; Aortofemoral runoffs: 20–90mL; Peripheral arteries: 15–30mL (max 250mL). IV: CT of head or body: 75–150mL or 100–150mL bolus infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL. CCTA (bolus inj with test bolus or bolus tracking): 50–150mL (4–7mL/sec); max 150mL.
Children
<12yrs: Intra-arterial for angiocardiography, cerebral arteriography, and visceral arteriography: 1–2mL/kg; max 4mL/kg.
Visipaque 320 Contraindications
Contraindications
Intrathecal use.
Visipaque 320 Boxed Warnings
Boxed Warning
Not for intrathecal use.
Visipaque 320 Warnings/Precautions
Warnings/Precautions
Have resuscitation equipment and trained personnel available. Homocystinuria: avoid. Severe renal impairment. Cardiovascular disease. CHF. Diabetes. Advanced vascular disease. Multiple myeloma/paraproteinaceous diseases. Pheochromocytoma. Catecholamine-secreting paragangliomas. Thyroid dysfunction (esp. children 0–3yrs); monitor. Homozygous sickle cell disease. History of severe cutaneous adverse reactions: avoid. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy. Nursing mothers: not recommended.
Visipaque 320 Pharmacokinetics
See Literature
Visipaque 320 Interactions
Interactions
May increase risk of metformin-induced lactic acidosis. Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Caution with concomitant beta-blockers. Do not use laxatives, diuretics, or preparatory dehydration prior to administration. Radioactive iodine uptake studies may not accurately reflect thyroid function for at least 16 days.
Visipaque 320 Adverse Reactions
Adverse Reactions
Rash, erythema, pruritus, scotoma; acute kidney injury, thromboembolic events, hypersensitivity reactions, others.
Visipaque 320 Clinical Trials
See Literature
Visipaque 320 Note
Not Applicable
Visipaque 320 Patient Counseling
See Literature
